New drug LY3451838 tested in healthy people for safety

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male participants must adhere to contraception restrictions * Female participants must be of non-childbearing potential due to: * Menopause: spontaneous amenorrhea for at least 12 months not induced by a medical condition such as anorexia nervosa and not taking medications that induced the amenorrhea (e.g., oral contraceptives, hormones, gonadotropin releasing hormone, anti-estrogens, selective estrogen receptor modulators, or chemotherapy) * Surgical sterilization * Have a body mass index of 18 to 35 kilograms per square meter (kg/m²) * Have clinical laboratory test results within normal reference range or with acceptable deviations * Have an estimated glomerular filtration rate greater than or equal to (≥) 60 milliliters per minute per 1.73 meters squared (mL/minute/1.73 m²) of body surface area * Have venous access sufficient to allow for blood sampling Exclusion Criteria: * Are currently enrolled in or discontinued from a clinical trial within the last 30 days, or have previously completed or withdrawn from this study * Have a history or presence of medical illness including, but not limited to, any cardiovascular, hepatic, respiratory, hematological, renal, endocrine, psychiatric or neurological disease, or any clinically significant laboratory abnormality * Have history of or presence of uncontrolled asthma, significant atopy, or significant rheumatological or autoimmune diseases * Have had lymphoma, leukemia, or any malignancy within the past 5 years, or breast cancer within the past 10 years (with some exceptions) * Have used, or intend to use some prescription or over the counter medications, including herbal medications within 14 days prior to dosing * Have an abnormality in the 12-lead electrocardiogram (ECG) or Fridericia's corrected QT (QTcF) * Show evidence of human immunodeficiency virus (HIV) and/or positive human HIV antibodies, hepatitis C and/or positive hepatitis C antibody, or hepatitis B and/or positive hepatitis B surface antigen * Have donated blood of more than 450 milliliters (mL) within the last 3 months * Are unwilling to stop alcohol consumption while resident in the Clinical Research Unit (CRU) * Have an average weekly alcohol intake that exceeds 21 units per week for males and 14 units per week for females (1 unit = 12 ounces (oz) or 360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits) * Current smoker of more than 10 cigarettes or equivalent per day and unable to stop smoking while in the CRU * Have an abnormal blood pressure * Have clinically significant proteinuria or hematuria * Positive findings for known drugs of abuse * Have received treatment with biologic agents within 3 months or 5 half-lives (whichever is longer) * Have clinically significant allergies, or intolerance to corticosteroids, or severe post treatment hypersensitivity reactions